Opendata, web and dolomites

AIMS-2-TRIALS SIGNED

Autism Innovative Medicine Studies – 2 – Trials

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AIMS-2-TRIALS project word cloud

Explore the words cloud of the AIMS-2-TRIALS project. It provides you a very rough idea of what is the project "AIMS-2-TRIALS" about.

social    horizon    global    behaviours    animal    repetitive    core    smes    attracts    pathophysiolog    million    hampered    fast    symptoms    medicine    trial    individuals    translation    industry    outcomes    agents    life    biomarkers    preclinical    span    accessible    successful    time    infancy    actions    forefront    quality    reliably    tailoring    linked    running    wins    carries    deficits    people    outcome    biological    interests    network    asd    networks    patient    progress    validate    stratification    qualify    translate    world    comorbidities    imi    clinical    adulthood    drugs    heterogeneous    limited    carry    ies    align    expertise    biologically    placebo    centres    sustainable    union    underlying    combination    drug    autism    ema    international    fails    treatments    neurodevelopmental    lack    restricted    subtypes    spectrum    models    molecular    fda    efforts    healthcare    designs    legacy    profile    depression    quick    first    vision    precision    populations    filings    disorder    create    communication    trials    2020    humans    ineffective    mechanisms    significantly    transform    achievements    helps    epilepsy    reduces   

Project "AIMS-2-TRIALS" data sheet

The following table provides information about the project.

Coordinator
KING'S COLLEGE LONDON 

Organization address
address: STRAND
city: LONDON
postcode: WC2R 2LS
website: www.kcl.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website https://www.aims-2-trials.eu/
 Total cost 113˙274˙914 €
 EC max contribution 54˙999˙998 € (49%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2016-10-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2023-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KING'S COLLEGE LONDON UK (LONDON) coordinator 20˙598˙874.00
2    SERVICIO MADRILENO DE SALUD ES (MADRID) participant 5˙411˙635.00
3    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 4˙635˙793.00
4    BIRKBECK COLLEGE - UNIVERSITY OF LONDON UK (LONDON) participant 2˙899˙831.00
5    INSTITUT PASTEUR FR (PARIS CEDEX 15) participant 2˙817˙986.00
6    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 2˙808˙026.00
7    UNIVERSITAT BASEL CH (BASEL) participant 1˙205˙000.00
8    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 1˙175˙481.00
9    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) participant 1˙022˙332.00
10    UNIVERSITEIT GENT BE (GENT) participant 958˙462.00
11    ZENTRALINSTITUT FUER SEELISCHE GESUNDHEIT DE (MANNHEIM) participant 924˙135.00
12    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 916˙023.00
13    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 851˙500.00
14    RIJKSUNIVERSITEIT GRONINGEN NL (GRONINGEN) participant 837˙500.00
15    UNIVERSITAET ULM DE (ULM) participant 805˙577.00
16    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 805˙000.00
17    JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN DE (FRANKFURT AM MAIN) participant 783˙500.00
18    UNIVERSIDADE DE COIMBRA PT (COIMBRA) participant 780˙299.00
19    ARTTIC FR (PARIS) participant 549˙525.00
20    DEMCON ADVANCED MECHATRONICS ENSCHEDE B.V. NL (ENSCHEDE) participant 482˙500.00
21    STELLENBOSCH UNIVERSITY ZA (STELLENBOSCH) participant 419˙543.00
22    THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN IE (DUBLIN) participant 392˙346.00
23    NOLDUS INFORMATION TECHNOLOGY BV NL (WAGENINGEN) participant 272˙500.00
24    AUTISME-EUROPE AISBL BE (BRUXELLES) participant 268˙600.00
25    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) participant 245˙000.00
26    UNIVERSITY OF GLASGOW UK (GLASGOW) participant 245˙000.00
27    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) participant 245˙000.00
28    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) participant 236˙625.00
29    FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA ES (BARCELONA) participant 203˙125.00
30    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN DE (MUENCHEN) participant 202˙500.00
31    BIOSCI CONSULTING BVBA BE (MAASMECHELEN) participant 192˙343.00
32    STICHTING BURO ECNP NL (UTRECHT) participant 187˙498.00
33    UPPSALA UNIVERSITET SE (UPPSALA) participant 149˙995.00
34    STARLAB BARCELONA SL ES (BARCELONA) participant 122˙500.00
35    Fondazione Stella Maris IT (Pisa) participant 68˙125.00
36    FUNDAZIOA POLICLINICA GIPUZKOA FUNDACION ES (SAN SEBASTIAN) participant 68˙125.00
37    UNIVERSIDAD DE SALAMANCA ES (SALAMANCA) participant 68˙125.00
38    UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS DE (GOETTINGEN) participant 68˙125.00
39    UNIVERSITY OF BRISTOL UK (BRISTOL) participant 51˙812.00
40    CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS FR (TOURS CEDEX 9) participant 24˙125.00
41    AUTISM SPEAKS INC. NON PROFIT CORPORATION US (Princeton NJ) participant 0.00
42    AUTISTICA UK (LONDON) participant 0.00
43    F. HOFFMANN-LA ROCHE AG CH (BASEL) participant 0.00
44    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
45    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
46    TEVA PHARMACEUTICAL INDUSTRIES LIMITED IL (PETACH TIVKA) participant 0.00
47    THE SIMONS FOUNDATION, INC US (NEW YORK) participant 0.00
48    UCB BIOPHARMA SRL BE (BRUXELLES) participant 0.00

Map

 Project objective

Autism Spectrum Disorder (ASD) is a heterogeneous neurodevelopmental condition affecting over five million people in the European Union. The combination of core symptoms (deficits in social-communication and repetitive and restricted behaviours and interests) and common comorbidities (e.g. epilepsy and depression) significantly reduces the quality of life and life-span of affected individuals. Currently there are no effective drug treatments for the core symptoms. Key factors that have hampered progress include; 1) limited understanding of the underlying pathophysiolog(ies); 2) lack of successful translation from animal models to humans; 3) testing of drugs with specific actions in biologically heterogeneous populations; 4) limited expertise of many European ASD centres in running large-scale clinical trials; and 5) trial designs (e.g. placebo effects).

Our vision, therefore, is to apply a precision medicine approach to ASD and improve patient outcomes by tailoring treatments to a patient’s biological profile. Our efforts will build on the achievements of 5 other IMI initiatives, 4 Horizon 2020 networks, and 6 SMEs for the first time to; 1) align global resources to validate and qualify stratification biomarkers from infancy to adulthood; 2) develop objective outcome measures that can be used in trials; 3) create a European-wide clinical trials network that reliably carries out studies able to support filings to the EMA/FDA; 4) carry out better targeted clinical trials linked to other international efforts – including quick wins or “fast fails” of ineffective agents; 5) translate molecular mechanisms and drug effects between preclinical models and particular subtypes of ASD.

Together we will bring Europe to the forefront of clinical research in ASD. Also we will provide a sustainable legacy that is accessible by others across the world, attracts industry into ASD, and helps transform healthcare.

 Deliverables

List of deliverables.
First report of Engagement, Dissemination and Communication Plan Websites, patent fillings, videos etc. 2020-04-16 12:28:43
Press Release Websites, patent fillings, videos etc. 2020-04-16 12:28:42
AIMS-2-TRIALS Website launched Websites, patent fillings, videos etc. 2020-04-16 12:28:42
Draft of Data Management plan Open Research Data Pilot 2020-04-16 12:28:42
SOPs finalised and e-data management systems established Documents, reports 2020-04-16 12:28:42
Clinical Trial Network (CTN) established and trained to GCP standards and ‘trial ready’ with a single point of contact Documents, reports 2020-04-16 12:28:42

Take a look to the deliverables list in detail:  detailed list of AIMS-2-TRIALS deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Inês Pote, Siying Wang, Vaheshta Sethna, Anna Blasi, Eileen Daly, Maria Kuklisova‐Murgasova, Sarah Lloyd‐Fox, Evelyne Mercure, Paula Busuulwa, Vladimira Stoencheva, Tony Charman, Steven C. R. Williams, Mark H. Johnson, Declan G. M. Murphy, Grainne M. McAlonan
Familial risk of autism alters subcortical and cerebellar brain anatomy in infants and predicts the emergence of repetitive behaviors in early childhood
published pages: 614-627, ISSN: 1939-3806, DOI: 10.1002/aur.2083
Autism Research 12/4 2020-04-16
2019 Charlotte Marie Pretzsch, Jan Freyberg, Bogdan Voinescu, David Lythgoe, Jamie Horder, Maria Andreina Mendez, Robert Wichers, Laura Ajram, Glynis Ivin, Martin Heasman, Richard A. E. Edden, Steven Williams, Declan G. M. Murphy, Eileen Daly, Gráinne M. McAlonan
Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder
published pages: 1398-1405, ISSN: 0893-133X, DOI: 10.1038/s41386-019-0333-8
Neuropsychopharmacology 44/8 2020-04-16
2019 Thomas Wolfers, Dorothea L. Floris, Richard Dinga, Daan van Rooij, Christina Isakoglou, Seyed Mostafa Kia, Mariam Zabihi, Alberto Llera, Rajanikanth Chowdanayaka, Vinod J. Kumar, Han Peng, Charles Laidi, Dafnis Batalle, Ralica Dimitrova, Tony Charman, Eva Loth, Meng-Chuan Lai, Emily Jones, Sarah Baumeister, Carolin Moessnang, Tobias Banaschewski, Christine Ecker, Guillaume Dumas, Jonathan O’Muir
From pattern classification to stratification: towards conceptualizing the heterogeneity of Autism Spectrum Disorder
published pages: 240-254, ISSN: 0149-7634, DOI: 10.1016/j.neubiorev.2019.07.010
Neuroscience & Biobehavioral Reviews 104 2020-04-16
2019 Pär Nyström, Emilia Thorup, Sven Bölte, Terje Falck-Ytter
Joint Attention in Infancy and the Emergence of Autism
published pages: 631-638, ISSN: 0006-3223, DOI: 10.1016/j.biopsych.2019.05.006
Biological Psychiatry 86/8 2020-04-16
2019 E.J.H. Jones, L. Mason, J. Begum Ali, C. van den Boomen, R. Braukmann, E. Cauvet, E. Demurie, R.S. Hessels, E.K. Ward, S. Hunnius, S. Bolte, P. Tomalski, C. Kemner, P. Warreyn, H. Roeyers, J. Buitelaar, T. Falck-Ytter, T. Charman, M.H. Johnson
Eurosibs: Towards robust measurement of infant neurocognitive predictors of autism across Europe
published pages: 101316, ISSN: 0163-6383, DOI: 10.1016/j.infbeh.2019.03.007
Infant Behavior and Development 57 2020-04-16
2018 Jamie Horder, Max Andersson, Maria A. Mendez, Nisha Singh, Ämma Tangen, Johan Lundberg, Antony Gee, Christer Halldin, Mattia Veronese, Sven Bölte, Lars Farde, Teresa Sementa, Diana Cash, Karen Higgins, Debbie Spain, Federico Turkheimer, Inge Mick, Sudhakar Selvaraj, David J. Nutt, Anne Lingford-Hughes, Oliver D. Howes, Declan G. Murphy, Jacqueline Borg
GABA A receptor availability is not altered in adults with autism spectrum disorder or in mouse models
published pages: eaam8434, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aam8434
Science Translational Medicine 10/461 2020-04-16
2019 Julian Tillmann, Antonia San José Cáceres, Chris H. Chatham, Daisy Crawley, Rosemary Holt, Bethany Oakley, Tobias Banaschewski, Simon Baron‐Cohen, Sven Bölte, Jan K. Buitelaar, Sarah Durston, Lindsay Ham, Eva Loth, Emily Simonoff, Will Spooren, Declan G. Murphy, Tony Charman, Jumana Ahmad, Sara Ambrosino, Bonnie Auyeung, Sarah Baumeister, Christian Beckmann, Thomas Bourgeron, Carsten Bours, M
Investigating the factors underlying adaptive functioning in autism in the EU‐AIMS Longitudinal European Autism Project
published pages: 645-657, ISSN: 1939-3806, DOI: 10.1002/aur.2081
Autism Research 12/4 2020-04-16
2019 Nico Bast, Tobias Banaschewski, Isabel Dziobek, Daniel Brandeis, Luise Poustka, Christine M. Freitag
Pupil Dilation Progression Modulates Aberrant Social Cognition in Autism Spectrum Disorder
published pages: , ISSN: 1939-3806, DOI: 10.1002/aur.2178
Autism Research 2020-04-16
2018 David M. Greenberg, Varun Warrier, Carrie Allison, Simon Baron-Cohen
Testing the Empathizing–Systemizing theory of sex differences and the Extreme Male Brain theory of autism in half a million people
published pages: 12152-12157, ISSN: 0027-8424, DOI: 10.1073/pnas.1811032115
Proceedings of the National Academy of Sciences 115/48 2020-04-16
2019 Covadonga M. Díaz-Caneja, Hugo Schnack, Kenia Martínez, Javier Santonja, Yasser Alemán-Gomez, Laura Pina-Camacho, Carmen Moreno, David Fraguas, Celso Arango, Mara Parellada, Joost Janssen
Neuroanatomical deficits shared by youth with autism spectrum disorders and psychotic disorders
published pages: 1643-1653, ISSN: 1065-9471, DOI: 10.1002/hbm.24475
Human Brain Mapping 40/5 2020-04-16
2019 Charlotte M Pretzsch, Bogdan Voinescu, Maria A Mendez, Robert Wichers, Laura Ajram, Glynis Ivin, Martin Heasman, Steven Williams, Declan GM Murphy, Eileen Daly, Gráinne M McAlonan
The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD)
published pages: 1141-1148, ISSN: 0269-8811, DOI: 10.1177/0269881119858306
Journal of Psychopharmacology 33/9 2020-04-16
2019 Štefan Holiga, Joerg F. Hipp, Christopher H. Chatham, Pilar Garces, Will Spooren, Xavier Liogier D’Ardhuy, Alessandro Bertolino, Céline Bouquet, Jan K. Buitelaar, Carsten Bours, Annika Rausch, Marianne Oldehinkel, Manuel Bouvard, Anouck Amestoy, Mireille Caralp, Sonia Gueguen, Myriam Ly-Le Moal, Josselin Houenou, Christian F. Beckmann, Eva Loth, Declan Murphy, Tony Charman, Julian Tillmann, Ch
Patients with autism spectrum disorders display reproducible functional connectivity alterations
published pages: eaat9223, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aat9223
Science Translational Medicine 11/481 2020-04-16
2019 Christine Austin, Paul Curtin, Austen Curtin, Chris Gennings, Manish Arora, Kristiina Tammimies, Johan Isaksson, Charlotte Willfors, Sven Bölte
Dynamical properties of elemental metabolism distinguish attention deficit hyperactivity disorder from autism spectrum disorder
published pages: , ISSN: 2158-3188, DOI: 10.1038/s41398-019-0567-6
Translational Psychiatry 9/1 2020-04-16
2019 Eva Loth, David W. Evans
Converting tests of fundamental social, cognitive, and affective processes into clinically useful bio‐behavioral markers for neurodevelopmental conditions
published pages: e1499, ISSN: 1939-5078, DOI: 10.1002/wcs.1499
Wiley Interdisciplinary Reviews: Cognitive Science 2020-04-16

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AIMS-2-TRIALS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AIMS-2-TRIALS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More